All genes represented in the Vantage panel are clinically relevant in several tumor types, although not every single gene included is relevant concretely for NSCLC: some of them are druggable, such as EGFR and BRAF; some have a potential for future targeted strategies, such as KRAS G12C [31], whereas others, such as STK11 and KEAP1 are clinically informative although cannot be targeted yet [32]. This evidence concerns the gene KEAP1 and neoplasm.